<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent studies have highlighted the involvement of the peripheral immune system in delayed cellular degeneration after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In the permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) model of <z:hpo ids='HP_0001297'>stroke</z:hpo>, the spleen decreases in size </plain></SENT>
<SENT sid="2" pm="."><plain>This reduction occurs through the release of splenic immune cells </plain></SENT>
<SENT sid="3" pm="."><plain>Systemic treatment with human umbilical cord blood cells (HUCBC) 24 h post-<z:hpo ids='HP_0001297'>stroke</z:hpo> blocks the reduction in spleen size while significantly reducing <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="4" pm="."><plain>Splenectomy 2 weeks prior to MCAO also reduces <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, further demonstrating the detrimental role of this organ in <z:hpo ids='HP_0001297'>stroke</z:hpo>-induced <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Activation of the sympathetic <z:mp ids='MP_0008912'>nervous</z:mp> system after MCAO results in elevated <z:chebi fb="2" ids="33567">catecholamine</z:chebi> levels both at the level of the spleen, through direct splenic innervation, and throughout the systemic circulation upon release from the adrenal medulla </plain></SENT>
<SENT sid="6" pm="."><plain>These <z:chebi fb="2" ids="33567">catecholamines</z:chebi> bind to splenic alpha and beta adrenoreceptors </plain></SENT>
<SENT sid="7" pm="."><plain>This study examines whether <z:chebi fb="2" ids="33567">catecholamines</z:chebi> regulate the splenic response to <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Male Sprague-Dawley rats either underwent splenic denervation 2 weeks prior to MCAO or received injections of <z:chebi fb="0" ids="3441">carvedilol</z:chebi>, a pan adrenergic receptor blocker, <z:chebi fb="1" ids="8364">prazosin</z:chebi>, an alpha1 receptor blocker, or <z:chebi fb="2" ids="8499">propranolol</z:chebi>, a beta receptor blocker </plain></SENT>
<SENT sid="9" pm="."><plain>Denervation was confirmed by reduced splenic expression of tyrosine hydroxylase </plain></SENT>
<SENT sid="10" pm="."><plain>Denervation prior to MCAO did not alter <z:mpath ids='MPATH_124'>infarct</z:mpath> volume or spleen size </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="2" ids="8499">Propranolol</z:chebi> treatment also had no effects on these outcomes </plain></SENT>
<SENT sid="12" pm="."><plain>Treatment with either <z:chebi fb="1" ids="8364">prazosin</z:chebi> or <z:chebi fb="0" ids="3441">carvedilol</z:chebi> prevented the reduction in spleen size, yet only <z:chebi fb="0" ids="3441">carvedilol</z:chebi> significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (p &lt; 0.05) </plain></SENT>
<SENT sid="13" pm="."><plain>These results demonstrate that circulating blood borne <z:chebi fb="2" ids="33567">catecholamines</z:chebi> regulate the splenic response to <z:hpo ids='HP_0001297'>stroke</z:hpo> through the activation of both alpha and beta adrenergic receptors </plain></SENT>
</text></document>